What type of study is this?

September 20, 2025Cancer Research

Abstract B066: TLR-agonist modified mesoporous silica nanoparticles stimulate T cell-mediated anti-cancer immune responses following intraperitoneal delivery in HLA-A 2.1 allele PDX ovarian cancer models in humanized NBSGW mice

View Full Paper

Ask AI

Bookmark

Intraperitoneal delivery of TLR-agonist modified nanoparticles significantly enhanced T cell responses in cancer models.
Flow cytometry revealed an increase in human T cell proportions from 12 to 23 weeks after treatment in humanized mice.
Ineffective intravenous delivery highlighted the need for regional administration of immune activators to combat tumors.
The observed rise in PD-1 expression with intravenous delivery indicates potential immune suppression in T cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical trial shows intraperitoneal delivery of TLR-agonist nanoparticles boosts immune response in HLA-A 2.1 models, suggesting targeted therapy potential.

Cite This Study

Serda et al. (2025) studied this question.

synapsesocial.com/papers/68d469ba31b076d99fa66284 https://doi.org/10.1158/1538-7445.ovarian25-b066

View Full Paper

Ask AI

Bookmark

Implication

Preclinical trial shows intraperitoneal delivery of TLR-agonist nanoparticles boosts immune response in HLA-A 2.1 models, suggesting targeted therapy potential.

Abstract B066: TLR-agonist modified mesoporous silica nanoparticles stimulate T cell-mediated anti-cancer immune responses following intraperitoneal delivery in HLA-A 2.1 allele PDX ovarian cancer models in humanized NBSGW mice

Key Points

Discussion

Implication

Cite This Study

Abstract B066: TLR-agonist modified mesoporous silica nanoparticles stimulate T cell-mediated anti-cancer immune responses following intraperitoneal delivery in HLA-A 2.1 allele PDX ovarian cancer models in humanized NBSGW mice

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider